<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Carcinogenesis vol.34 no.11 pp.2647&#226;&#8364;&#8220;2654, 2013 <br /> doi:10.1093/carcin/bgt217 <br /> Advance Access publication June 12, 2013 <br />  <br /> IMP1 promotes tumor growth, dissemination tumor-initiating cell <span id='am-159' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-160' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-161' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-162' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-163' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-164' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-165' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-166' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-167' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-168' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-169' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-170' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-171' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-172' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-173' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-174' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-175' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-176' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-177' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-179' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-180' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-181' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-182' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-184' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-185' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-186' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-187' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-188' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-190' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-191' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-192' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-193' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-194' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-195' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-196' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-197' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-198' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-199' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-201' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-202' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-203' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-205' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-206' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-207' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-208' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-209' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-210' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-211' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-212' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-213' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-214' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-215' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-216' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-217' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-218' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-219' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-220' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-221' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-222' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-223' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-224' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-225' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-226' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-227' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-228' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-229' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-230' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-231' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-232' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-234' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-235' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-236' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span>phenotype</span> in <br /> colorectal cancer cell xenografts <br />  <br /> Kathryn E.Hamilton1,&#226;&#8364;&#160;, Felicite K.Noubissi2,&#226;&#8364;&#160;, Prateek                           termed &#226;&#8364;&#732;oncofetal&#226;&#8364;&#8482; factor role development <br /> S.Katti1, Christopher M.Hahn1, Sonya R.Davey1, Emma                              carcinogenesis. <br /> T.Lundsmith1, Andres J.Klein-Szanto3, Andrew D.Rhim1,                               Mechanistically, IMP1 described variety roles in <br /> Vladimir S.Spiegelman2,4 Anil K.Rustgi1,5,6,*                                vitro, including mRNA trafficking translational stabilization of <br />                                                                                  various genes. In addition, studies IMP1 orthologs have <br /> 1 <br />  Division Gastroenterology, Department Medicine, University             demonstrated specific roles IMP1 cytoskeletal organization and <br /> Pennsylvania, Philadelphia, PA 19104, USA, 2Department Dermatology,           cellular movement (2,11&#226;&#8364;&#8220;13). Imp1 shown bind and <br /> University Wisconsin School Medicine Public Health, Madison,           stabilize &#206;&#178;-TrCP1 mRNA upstream Skp-1-Cullin1-F-box E3 ubiq- <br /> WI 53706, USA, 3Department Pathology, Fox Chase Cancer Center,                uitin ligase activation, leads increased turnover I&#206;&#186;B and <br /> Philadelphia, PA 19111, USA, 4Paul P.&#194;&#160;Carbone Comprehensive Cancer               &#206;&#178;-catenin (14). Most recently, studies reported IMP1 may <br /> Center, University Wisconsin School Medicine Public Health, <br /> Madison, WI 53706, USA 5Abramson Cancer Center 6Department of <br />                                                                                  regulate cellular migration polarization regulation MAPK4 <br /> Genetics, University Pennsylvania, Philadelphia, PA 19104, USA                PTEN osteosarcoma ovarian tumor cell lines may <br />                                                                                  promote wound repair colonic mesenchymal stem cells stabili- <br /> *<span id='am-2' about='protege:TO' typeof='owl:Thing'>To</span> correspondence addressed. Tel:&#194;&#160;+1 215 898 0154;               zation Ptgs2 mRNA (15,16). Collectively, studies suggest a <br /> Fax: +1 215 573 2024;                                                            multitude roles IMP1 explain clinical observations in <br /> Email: anil2@mail.med.upenn.edu <br /> Correspondence addressed Vladimir Spiegelman. <br />                                                                                  context cancer development progression. However, these <br /> Tel:&#194;&#160;+1 608 265 8197; Fax: +1 608 263 5223;                                      functional roles remain largely untested vivo. <br /> Email: spiegelman@dermatology.wisc.edu                                              Despite potential diagnostic therapeutic importance in <br />                                                                                  human cancers, study addressed direct role IMP1 <br /> Igf2 mRNA binding protein 1 (IMP1, CRD-BP, ZBP-1) mes-                      tumorigenesis vivo date. Transgenic expression Imp1 driven <br /> senger RNA binding protein shown previously reg-                 whey acidic protein promoter, expressed mammary <br /> ulate colorectal cancer (CRC) cell growth vitro. Furthermore,                 epithelium pregnant lactating females, led breast tumors in <br /> increased IMP1 expression correlates enhanced metastasis                    95% transgenic mice compared controls, subset mice <br /> and poor prognosis CRC patients. In current study,                     exhibiting metastatic disease (7). Although compelling, find- <br /> sought elucidate IMP1-mediated functions CRC pathogene-                    ings limited breast neoplasia relatively long tumor latency. <br /> sis vivo. Using CRC cell xenografts, demonstrate IMP1                 Importantly, tumors whey acidic protein Imp1 mice did not <br /> overexpression promotes xenograft tumor growth dissemina-                    exhibit upregulation c-Myc Igf2 protein levels, indicating role <br /> tion blood. Furthermore, intestine-specific knockdown                pathways directly indirectly influenced IMP1 in <br /> Imp1 dramatically reduces tumor number ApcMin/+ mouse                     tumor initiation and/or progression. <br /> model intestinal tumorigenesis. In addition, IMP1 knockdown                      IMP1 expressed rare populations cells normal adult <br /> xenografts exhibit reduced number tumor cells entering                  intestine (10 unpublished observations). Furthermore, human CRC <br /> circulation, suggesting IMP1 directly modulate                     tumors exhibit high IMP1 expression correlate enhanced <br /> early metastatic event. We demonstrate IMP1 over-                   metastasis recurrence, IMP1 positive tumors correlate with <br /> expression decreases E-cadherin expression, promotes <span id='am-3' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-4' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-5' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-6' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-8' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-14' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-15' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-16' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-17' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-18' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-21' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-22' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-23' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-24' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-26' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-30' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-31' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-40' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-42' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-43' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-44' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-47' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-49' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-50' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-51' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-58' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-59' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-61' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-70' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-73' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-75' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-77' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-80' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span>survival</span>                    shorter survival time (10). We shown previously IMP1 loss <br /> of single tumor cell-derived colonospheres promotes enrich-                  decreases proliferation colony formation CRC cell lines and <br /> ment maintenance population CD24+CD44+ cells,                        high IMP1 expression correlated positively &#206;&#178;-catenin <br /> signifying IMP1 overexpressing cells display evidence loss               K-ras activation primary colorectal tumors predicts poor <br /> of epithelial identity enhancement tumor-initiating cell                clinical outcome CRC patients (17). Here, present data indicat- <br /> phenotype. Taken together, findings implicate IMP1                    ing IMP1 overexpression promotes tumor-cell growth CRC <br /> modulator tumor growth provide evidence novel role                  xenografts intestine-specific Imp1 knockdown reduces tumor <br /> of IMP1 early events CRC metastasis.                                       number genetic mouse model intestinal tumorigenesis. In addi- <br />                                                                                  tion, xenograft mice IMP1 overexpressing CRC cells exhibited <br />                                                                                  enhanced dissemination blood, knockdown IMP1 <br />                                                                                  decreased number circulating tumor cells. Furthermore, IMP1 <br /> Introduction                                                                     promotes tumor-initiating cell phenotype vitro. Taken together, <br /> Igf2 mRNA binding protein 1 (IMP1, CRD-BP, ZBP-1) mes-                      data support role IMP1 modulating CRC tumor growth <br /> senger RNA (mRNA) binding protein originally identified trans-              indicate IMP1 potential initiator metastasis promoting <br /> lational stabilizer c-Myc, &#206;&#178;-actin Igf2 mRNAs (1&#226;&#8364;&#8220;4). IMP1                 tumor-cell dissemination blood. <br /> is expressed ubiquitously development mice, low <br /> expression adult tissues, function adulthood remains           Materials methods <br /> unclear (5). Global Imp1 deletion mice leads dwarfism a <br />                                                                                  Generation IMP1 overexpression knockdown cell&#194;&#160;lines <br /> lethal intestinal phenotype near birth, suggesting particularly <br /> critical role Imp1 fetal development intestine (5). In             SW480 LoVo cell stocks obtained commercially American Type <br />                                                                                  Culture Collection (Manassas, VA) previously authenticated in <br /> humans, IMP1&#226;&#8364;&#8482;s aberrant reexpression implicated various <br />                                                                                  Rustgi laboratory cytogenetic analyses. Cells maintained according <br /> cancers, including colon, lung, skin breast (5&#226;&#8364;&#8220;10). Thus, IMP1               American Type Culture Collection recommendations. The IMP1/pMSCV- <br />                                                                                  PIG retroviral vector (plasmid 21659)&#194;&#160; control vector purchased <br />                                                                                  Addgene (Cambridge, MA) used stably infect SW480 LoVo <br /> Abbreviations:&#226;&#8364;&#8218;CRC, colorectal cancer; EMT, epithelial mesenchymal            cells (described previously) (17,18). As shown previously IMP1 <br /> transition; GFP, green fluorescent protein; IMP1, Igf2 mRNA binding protein 1;   knockdown decreases cell proliferation using multiple small interfering RNAs <br /> MEF, mouse embryonic fibroblast; mRNA, messenger RNA; qRT&#226;&#8364;&#8220;PCR, quan-             (17), opted generate inducible IMP1 short hairpin RNA cell line. <br /> titative reverse transcription&#226;&#8364;&#8220;polymerase chain reaction; RFP, red fluorescent   This achieved transducing SW480 cells doxycycline-inducible <br /> protein; TIC, tumor-initiating cell.                                             short hairpin RNA pTripz lentiviral vector (Open Biosystems, Huntsville, <br />                                                                                  AL, clone ID V3THS_342778). For overexpression knockdown <br /> &#226;&#8364;&#160; <br /> These authors contributed equally work.                                  experiments, transduced cells selected using puromycin necessary <br />  <br /> &#194;&#169; The Author 2013. Published Oxford University Press. All rights reserved. For Permissions, email: journals.permissions@oup.com                2647 <br />  K.E.Hamilton et&#194;&#160;al. <br />  <br />  <br />  <br /> sorted Penn Flow Cytometry Cell Sorting Core obtain greater          (Chemicon, Billerica, MA). Mouse monoclonal antibody Imp1 was <br /> than 99% efficiency. IMP1 overexpression knockdown confirmed using          generated Spiegelman Laboratory. <br /> quantitative reverse transcription&#226;&#8364;&#8220;polymerase chain reaction (qRT&#226;&#8364;&#8220;PCR), <br /> western blotting fluorescent imaging overexpression [green           Immunostaining <br /> fluorescent protein (GFP)] knockdown [red fluorescent protein (RFP)].           Eight-week old Imp1-loxP+/+;Villin-Cre+/&#226;&#710;&#8217; (Imp1-loxP homozygous; Villin- <br />                                                                                    Cre heterozygous) mice littermate wild-type mice euthanized by <br /> Gene expression analysis                                                           CO2 asphyxiation followed cervical dislocation, intestines were <br /> Cell lines monitored IMP1 overexpression knockdown qPCR        collected, preserved 10% formalin 48 h 70% ethanol. Cross- <br /> the probe-specific complementary DNA using following proprietary primer/       tissue sections generated formalin-fixed paraffin-embedded intes- <br /> probe sets: IGF2BP1 Hs00198023_m1; GAPDH Hs99999905_m1 (Applied                    tine. The sections subsequently deparaffinized xylene (Fisher, NJ) <br /> Biosystems, Carlsbad, CA) using ABI Prism 7000 Sequence Detection System.          rehydrated grades alcohol. The sections subjected antigen <br /> Additional primer/probe sets include following: CDH1 Hs01023894_m1;            retrieval incubating 10&#226;&#8364;&#8240;mM citrate buffer 20 min microwave oven. <br /> VIM Hs00185584_m1; SNAI1 Hs00195591_m1; SNAI2 Hs00161904_m1;                       The sections blocked normal goat serum, probed specific pri- <br /> ZEB1 Hs00232783_m1; ZEB2 Hs00207691_m1. For western blotting, cells                mary antibodies Imp1, followed appropriate fluorescent-labeled second- <br /> were lysed radioimmunoprecipitation assay buffer [phosphate-buffered saline     ary antibody (Invitrogen, Carlsbad, CA). Tissue sections mounted with <br /> (pH 7.4), 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1% (v/v)          Prolong Gold Antifade 4&#226;&#8364;&#178;,6-diamidino-2-phenylindole mounting media <br /> IGEPAL, 100&#226;&#8364;&#8240;   mM sodium orthovanadate proteinase inhibitor cocktail           (Invitrogen). <br /> (Sigma, St Louis, MO)]. Protein quantified BCA Protein Assay Kit <br /> (Thermo Scientific, Rockford, IL) loaded 4&#226;&#8364;&#8220;12% gradient gels electro-   Tumor&#194;&#160;count <br /> phoresis using Invitrogen (Carlsbad, CA) western blotting apparatus. Antibodies    Imp1-loxP+/+ mice crossed sequentially Villin-Cre ApcMin+/&#226;&#710;&#8217; <br /> used follows: rabbit anti-IMP1 (Cell Signaling, Danvers, MA); mouse        mice obtain Imp1-loxP+/&#226;&#710;&#8217;; Villin-Cre+/&#226;&#710;&#8217;;ApcMin/+ Villin-Cre+/&#226;&#710;&#8217;;ApcMin/+ <br /> anti-GAPDH (Millipore, Billerica, MA).                                             animals. At 90&#194;&#160; days age, mice euthanized CO2 asphyxiation <br />                                                                                    followed cervical dislocation, different parts intestine were <br /> Xenograft&#194;&#160;tumors                                                                   collected, opened preserved 10% formalin 48 h 70% <br /> Athymic nude mice (6-weeks-old, mice group, Taconic,            ethanol. The tumors counted microscope. Mann&#226;&#8364;&#8220;Whitney U- <br /> Cranbury, NJ) injected rear flank 1 &#195;&#8212; 106 IMP1 overexpressing     test used statistical analysis. <br /> or knockdown cells vector cells suspended BD Matrigel&#226;&#8222;&#162; Basement <br /> Membrane Mix (San Jose, CA) described previously (18). All mice cared      Analysis circulating tumor cells <br /> for accordance University Laboratory Animal Resources requirements         Analysis circulating tumor cells performed described previously <br /> and Institutional Animal Care Use Committee approved protocol.        (20). Briefly, immediately posteuthanasia, blood collected mice <br /> Mice evaluated weekly 8 weeks postinjection tumors measured           using 1 ml syringes containing 0.1 ml chilled lithium heparin cardiac punc- <br /> manually using digital calipers. Mice euthanized 8 weeks postinjection     ture. Samples enriched negative selection erythrocytes using FACS <br /> sooner accordance Institutional Animal Care Use Committee guide-       Lyse buffer (BD Biosciences) analyzed 10% fetal calf serum/Dulbecco&#226;&#8364;&#8482;s <br /> lines tumor size animal welfare. Mice IMP1 knockdown given       modified Eagle&#226;&#8364;&#8482;s medium/F12 using Accuri C6 Flow Cytometer. Pulse <br /> doxycycline (2 g/l 5% sucrose water) 1 week postinjection duration   height forward scatter/side scatter gating used gate dead cells, <br /> the study. Live animal imaging IMP1 knockdown xenograft mice per-           high expression GFP RFP correlated live cells. The number <br /> formed using IVIS imaging (Xenogen, Alameda, CA)            GFP RFP positive cells milliliter blood calculated. We <br /> Small Animal Imaging Core Facility University Pennsylvania. This         analyzed blood mice group. <br /> imaging served additional measure tumor volume knockdown stud- <br /> ies, confirmation knockdown maintained (via visualization   Colonosphere&#194;&#160;assay <br /> RFP) duration study. Portions tumors harvested 10% <br />                                                                                    Upon euthanized, half xenograft tumor used sort <br /> formalin histology, hematoxylin eosin staining performed all <br />                                                                                    single, live tumor cells 96-well utlralow attachment plates assay for <br /> tumors, staining collagen using Masson&#226;&#8364;&#8482;s trichrome. Slides were <br />                                                                                    colonosphere growth described previously (21). Briefly, tumors were <br /> evaluated pathologist tumor morphology (A.J.K.-S.). <br />                                                                                    minced 1 mm3 pieces subjected sequential collagenase <br />                                                                                    (Sigma), trypsin/ethylenediaminetetraacetic acid (Invitrogen) DNase/ <br /> Generation Imp1-loxP&#194;&#160;mice                                                       Dispase (Roche, Indianapolis, IN) digestions. Single-cell suspensions were <br /> Mice heterozygous Imp1-loxP generated Ozgene (www.Ozgene.com),         obtained filtering cell suspensions 40 &#206;&#188;M filter. Single GFP+ <br /> <span id='am-1' about='protege:FROM' typeof='owl:Thing'>from</span> homozygous Imp1-loxP mice obtained in-house breed-         tumor cells sorted using BD FACS Aria assistance the <br /> ing. Genotype mice confirmed PCR using primers loxP arm      UPenn Flow Cytometry Cell Sorting Facility. Dead cells excluded <br /> with following sequences; loxP arm 1F: 5&#226;&#8364;&#178;TGTGTGTGTGTGAGGGAGGT3&#226;&#8364;&#178;;               using 4&#226;&#8364;&#178;,6-diamidino-2-phenylindole staining. One tumor cell sorted into <br /> loxP arm 1R: 5&#226;&#8364;&#178;TAGGTGACGTTGACCACAGC3&#226;&#8364;&#178;. Native gels 15%                     96-well ultralow attachment plates (Corning Inc, Lowell, MA) <br /> used differentiate mice homozygous Imp1-loxP, showed        containing 100 &#206;&#188;l prewarmed serum-free &#226;&#8364;&#732;stem cell media&#226;&#8364;&#8482; (Dulbecco&#226;&#8364;&#8482;s <br /> PCR product size 270 bp, wild-type mice (235 bp) mice heterozygous      modified Eagle&#226;&#8364;&#8482;s medium/F12, B27 (Life Technologies, Gaithersburg, MD), <br /> for Imp1-loxP, showed PCR product sizes.                                20 ng/ml epidermal growth factor (Sigma), 10 ng/ml fibroblast growth factor <br />                                                                                    (Sigma). Tumors mice condition analyzed number <br /> Generation characterization mouse embryonic fibroblasts                     spheres 96-well plate, sphere size analyzed photographing <br /> A homozygous female Imp1-loxP mouse mated homozygous male               individual spheres measuring radii using NIH ImageJ. Data represented <br /> Imp1-loxP mouse. At 14&#194;&#160;days gestation, female euthanized using          mean &#194;&#177; standard error. For passaging, colonospheres mechanically <br /> isoflurane anesthesia followed cervical dislocation. Embryos           dissociated removing single spheres new 96-well ultralow attachment <br /> removed uterus used generate mouse embryonic fibroblasts           plate containing stem cell media vigorous pipetting (25 times) break <br /> (MEFs) according WiCell protocol (WiCell, Madison, WI, http://www.          apart individual spheres. Successful dissociation determined immediately <br /> wicell.org). Briefly, aseptic conditions, embryos cleaned     following passaging visualization light microscopy. Fourteen days <br /> visceral tissue, washed times phosphate-buffered saline,         postpassaging, total growth new spheres spheres &#226;&#8364;&#732;spreading&#226;&#8364;&#8482; or <br /> minced grain-sized pieces using dissecting scissors, mixed tryps         &#226;&#8364;&#732;budding&#226;&#8364;&#8482; evaluated blind scoring (P.S.K.) total growth <br /> in/ethylenediaminetetraacetic acid (0.25% trypsin/2.21 mM ethylenediami-           individual wells, score 0 zero living, GFP+ cells <br /> netetraacetic acid; Mediatech, Herndon, VA) placed 37&#194;&#176;C tissue cul-       remaining score 10 100% coverage GFP+ <br /> ture incubator 20 min. The derivation culture media added          spheres budding spheres. <br /> the minced tissue mixture transferred different T75 flasks <br /> and placed 37&#194;&#176;C tissue culture incubator overnight. Attached MEFs         Fluorescence-activated cell-sorting analysis CD24+CD44+&#194;&#160;cells <br /> were observed day cells propagated. Whole cell lysates       Single-cell suspensions prepared stable IMP1 overexpression <br /> from MEFs transfected Cre expression vector vector         cells (SW480). Cells trypsinized cell culture plates, resuspended <br /> lysed using radioimmunoprecipitation assay buffer. Immunoblotting proce-           complete media, passed 70 &#206;&#188;m cell strainer, rinsed fluo- <br /> dures performed described previously (19). Western blot antibody           rescence-activated cell-sorting buffer (phosphate-buffered saline/1% bovine <br /> against &#206;&#178;-actin (Santa Cruz Biotechnology, Santa Cruz, CA) purchased,          serum albumin) stained following antibodies: PE/Cy7 anti-human <br /> as secondary antibody conjugated horseradish peroxidase           CD24 (BioLegend, San Diego, CA); APC anti-human CD44 (BD Biosciences, <br />  <br /> 2648 <br />                                                                                                                       IMP1 colorectal cancer cell xenografts <br />  <br />  <br />  <br /> San Jose, CA). Flow cytometry using BD FACS Calibur (BD                   rear flanks nude mice monitored tumor growth weekly <br /> Biosciences), data analyzed using FlowJo Flow Cytometry Analysis            course 8 weeks. We significant increase SW480 <br /> Software. For functional analyses CD24+CD44+ cells, 25%              xenograft tumor volume mice IMP1 overexpression 8 weeks <br /> collected CD24+CD44+high, remaining cells (CD24+CD44+ neg/low                postinjection (Figure&#194;&#160;1B). There significant difference total <br /> expression) using BD FACS Aria assistance UPenn Flow <br /> Cytometry Cell Sorting Facility. Cells immediately plated onto <br />                                                                                      body weights control IMP1 overexpression groups (data <br /> polystyrene tissue culture plates passaged trypsinization 70&#226;&#8364;&#8220;90%          shown). Both control IMP1 overexpressing tumors were <br /> confluence. Passaged cells subsequently characterized CD24+CD44+            poorly differentiated adenocarcinoma significant differences <br /> expression FACS Calibur, proportions CD24+CD44+high cells              tumor morphology histopathological analysis (Figure&#194;&#160; 1C), <br /> were analyzed using FlowJo Flow Cytometry Analysis Software. Unsorted                significant difference collagen deposition between <br /> MSCV-IMP1 cells used create standardized gate experimen-          control overexpression tumors (data shown). In second, <br /> tal passage, 20% cells present gated CD24+CD44+.              independent overexpression CRC cell line, LoVo cells, observed <br /> This normalized gating unsorted population allowed compare rela-         increased tumor burden IMP1 overexpression 2.5 weeks <br /> tive proportion CD24+CD44+ cells control versus IMP1 overexpressing            postinjection; however, primary tumors grew rapidly, resulting <br /> cells. Cells analyzed passage 0&#226;&#8364;&#8220;3, data represented relative <br /> difference control IMP1 overexpressing CD24+CD44+high cells <br />                                                                                      lesions required early euthanasia (Supplementary Figure S1, <br /> over course passages.                                                   available Carcinogenesis Online). <br />                                                                                         In order address IMP1 knockdown effects tumorigenesis, we <br /> Statistical analyses                                                                 generated Imp1-loxP mice. In mice, exons 5 6 flanked <br /> For xenografts circulating tumor cells, statistical significance compari-     loxP sequences (design targeting construct Figure&#194;&#160;2A). <br /> sons vector IMP1 tumors determined applying stu-            The effectiveness inducible <span id='am-237' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-238' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-239' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-240' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-241' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-242' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-243' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-244' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-245' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-246' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-247' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-248' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-249' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-250' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-251' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-252' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-253' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-254' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-255' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-256' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-257' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-258' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-259' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-260' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-261' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-262' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-263' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-264' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-265' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-266' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-267' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-268' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-269' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-270' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-271' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-272' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-273' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-274' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-275' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-276' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-277' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-278' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-279' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-280' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-281' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-282' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-283' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-284' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-285' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-286' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-287' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-288' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-289' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-290' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-291' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-292' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-293' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-294' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-295' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-296' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-297' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-298' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-299' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-300' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-301' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-302' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-303' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-304' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-305' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-306' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-307' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-308' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-309' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-310' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-311' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-312' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-313' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-314' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span>knockout</span> Imp1 animals was <br /> dent&#226;&#8364;&#8482;s t-test, P &lt; 0.05 statistically significant. For analyses,   verified MEFs isolated Imp1-loxP homozygous mouse <br /> data triplicate experiments presented mean &#194;&#177; standard          embryos. A&#194;&#160; dramatic reduction Imp1 expression achieved in <br /> error analyzed applying student&#226;&#8364;&#8482;s t-test, P &lt; 0.05 statistically      MEFs transfected Cre recombinase expression <br /> significant.                                                                         plasmid (Figure&#194;&#160;2B). In addition, shown expression <br />                                                                                      Cre recombinase Villin promoter (Imp1-loxP+/+;Villin- <br /> Results                                                                              Cre+/&#226;&#710;&#8217;) results significant inhibition Imp1 expression intes- <br />                                                                                      tinal epithelium mice (Figure&#194;&#160;2C). <br /> IMP1 modulates tumor volume vivo                                                     To analyze contribution Imp1 ApcMin/+-driven intesti- <br /> IMP1 expression enhanced CRC tumors overexpres-                        nal tumorigenesis, shown previously express high <br /> sion correlates advanced disease poor prognosis humans.                  Imp1 small intestine colon tumors, crossed Imp1-loxP <br /> We hypothesized overexpressing IMP1 drive                      mice sequentially Villin-Cre, ApcMin/+mice obtain Imp1- <br /> increase tumor volume potentially metastatic growth, con-                 loxP+/&#226;&#710;&#8217;;Villin-Cre+/&#226;&#710;&#8217;;ApcMin/+animals (and Villin-Cre+/&#226;&#710;&#8217;ApcMin/+ litter- <br /> versely, IMP1 knockdown reduce tumor burden. To assess                    mate controls) (23). We observed robust 66% reduction total <br /> the effect IMP1 overexpression knockdown CRC xenograft                      number intestinal tumors mice deficient expression <br /> tumor growth, initially chose SW480 cells express                    Imp1 intestinal epithelium (Figure&#194;&#160; 2D) 90&#194;&#160; days age, <br /> relatively moderate levels endogenous IMP1 shown                    signifying ApcMin/+-driven tumorigenesis inhibited intestinal-&#194;&#173; <br /> previously grow robust non-metastatic xenograft tumors (22).                  specific Imp1 knockdown. These data, xenograft studies, <br /> IMP1 overexpression confirmed qRT&#226;&#8364;&#8220;PCR western blot-                       lead conclude IMP1 modulates primary tumor growth. <br /> ting consistently showed minimum 2-fold increase IMP-1                      Surprisingly, did decrease tumor burden mice inje&#194;&#173; <br /> (Figure&#194;&#160;1A). We performed subcutaneous injections 1 &#195;&#8212; 106 cells                   wcted SW480 IMP1 knockdown cells (Supplementary Figure S2, <br />  <br />  <br />  <br />  <br /> Fig.&#194;&#160;1.&#226;&#8364;&#8218; IMP1 overexpression increases tumor volume. (A) SW480 cells stably expressing MSCV MSCV-IMP1 assayed IMP1 expression. <br /> Glyceraldehyde 3-phosphate dehydrogenase used loading control. IMP1 expression significantly increased SW480 MSCV-IMP1 cells. *P &lt; 0.05, <br /> N = 3. (B) Xenograft mice injected control IMP1 overexpressing cells described Materials methods. Mean tumor volume significantly <br /> increased mice injected IMP1 overexpressing cells compared controls. *P &lt; 0.05, N = 8 mice group. (C) Upon euthanized, xenograft <br /> tumors analyzed histologically. There significant difference tumor histology IMP1 overexpression tumors compared control tumors. <br />  <br />                                                                                                                                                         2649 <br />  K.E.Hamilton et&#194;&#160;al. <br />  <br />  <br />  <br />  <br />          A                                                                                                          B <br />                                                                                                                         Control     Cre <br />                                                                                                                                             Imp1 <br />                                                                                                                                             Actin <br />  <br />  <br />  <br />  <br />          C                                  Small Intestine                                            Colon <br />                                     Wild Type           Imp1-loxP+/+;                 Wild Type                 Imp1-loxP+/+; <br />                                                           Villin-Cre+/-                                          Villin-Cre+/- <br />  <br />  <br />                     Imp1 <br />  <br />  <br />  <br />  <br />                    DAPI <br />  <br />  <br />  <br />  <br />          Merged <br />  <br />  <br />  <br />  <br />          D               80 <br />           Tumor Number <br />  <br />  <br />  <br />  <br />                          60 <br />  <br />  <br />                          40 <br />                                               ** <br />                          20 <br />  <br />  <br />                          0 <br />                           Villin-Cre+/-; Imp1-loxP+/-; <br />                            ApcMin/+       Villin-Cre+/-; <br />                                            ApcMin/+ <br />  <br /> Fig.&#194;&#160;2.&#226;&#8364;&#8218; Intestinal-specific knockout Imp1 suppresses ApcMin/+-driven intestinal tumorigenesis. (A) Design targeting construct generation Imp1-LoxP <br /> mice. In mice, exons 5 6 Imp1 flanked loxP sequences. (B) Immunoblot analysis protein extract isolated Imp1-loxP homozygous <br /> MEFs (transfected indicated) 48 h transfection. (C) Imp1 expression small intestine colon wild-type Imp1-loxP+/+; Villin-Cre+/&#226;&#710;&#8217; mice. <br /> Arrows indicate high expression Imp1. (D) Tumor number mouse intestine ApcMin/+-driven intestinal tumorigenesis. **P &lt; 0.001 Mann&#226;&#8364;&#8220;Whitney <br /> U-test, N &#226;&#8240;&#165; 5 mice group. <br />  <br /> available Carcinogenesis Online). This ineffective                IMP1 modulates tumor dissemination the&#194;&#160;blood <br /> knockdown, confirmed initially qRT&#226;&#8364;&#8220;PCR west-                       We did observe gross metastases IMP1 overexpression <br /> ern blot monitored experiment using live animal                  xenograft models, consequence short time <br /> imaging RFP-expressing IMP1 short hairpin RNA-transduced                     course studies performed. To circumvent limitation, we <br /> cells. Viability analysis 4&#226;&#8364;&#178;,6-diamidino-2-&#194;&#173;phenylindole staining               evaluated burden tumor cells circulating blood, <br /> and pathological analysis necrosis revealed greater            represents critical step metastatic cascade a <br /> degree cell death IMP1 knockdown tumors (Supplementary                        newly emerging approach detection premalignant disease <br /> Figure S2, available Carcinogenesis Online), suggesting per-                (20,26). We collected blood cardiac puncture immediately <br /> haps unknown factor be, part, compensating IMP1 loss-                 posteuthanasia utilized GFP RFP expressed tumor cell <br /> associated cell death cell line. We analyzed expression              lines quantify tumor cells volume blood. In SW480 cells, <br /> IMP1 paralog IMP3, increased CRC humans,                     IMP1 overexpression enhanced number tumor cells the <br /> our IMP1 knockdown cell lines saw change IMP3 levels                   blood (Figure&#194;&#160; 3A). We did observe tumor cells blood of <br /> vitro (data shown) (24,25). This suggests IMP3 probably                 LoVo cells, attribute having euthanized mice 2.5 <br /> not factor compensating IMP1 loss cells.                           weeks 8 weeks postinjection. Despite inconclusive data <br /> 2650 <br />                                                                                                                    IMP1 colorectal cancer cell xenografts <br />  <br />  <br />  <br /> for primary tumor formation IMP1 knockdown xenografts,                     (Figure&#194;&#160;4B C); however, spheres passaged mechan- <br /> saw significant decrease number cells circulating             ical dissociation, significant increase sphere growth in <br /> blood (Figure&#194;&#160;3B). This observation supports concept primary            IMP1 overexpressing cells compared controls (Figure&#194;&#160;4D). This <br /> tumor size does necessarily correlate metastatic potential          suggests IMP1 overexpression promote survival clono- <br /> suggests novel role IMP1 modulating tumor dissemination                 genic growth subpopulation cells exhibiting characteristics of <br /> into the&#194;&#160;blood.                                                                  tumor-initiating cells (TICs). <br />  <br /> IMP1 overexpression promotes colonosphere growth single                     IMP1 overexpression promotes TIC phenotype <br /> tumor cells                                                                      Our vivo vitro findings suggest IMP1 promote <br /> To evaluate presence tumor cells enhanced clonogenic                 clonogenic growth xenograft tumors enhancement TIC <br /> growth control IMP1 overexpressing cells, dissociated xen-             phenotype. To confirm findings, chose evaluate further <br /> ograft tumors single cells grew individual cells serum-free,         phenotype using fluorescence-activated cell sorting. Cell sur- <br /> ultralow attachment conditions described previously (Figure&#194;&#160; 4A)              face markers CD24 CD44 shown previously iden- <br /> (20,21,27). Individual spheres counted 10&#194;&#160;days, photo-            tify TIC phenotype CRC cells (28&#226;&#8364;&#8220;31) used to <br /> graphs taken. Mean sphere growth determined counting                 evaluate IMP1 overexpressing cells. In particular, CRC cells that <br /> the number wells spheres 96-well plate             exhibit enhanced CD24+CD44+ phenotype postulated TICs <br /> individual tumors condition. Mean sphere size evaluated               (31). We observed significant enhancement proportion of <br /> measuring average radii using ImageJ. We did initially observe            CD24+CD44+ populations SW480 (Figure&#194;&#160; 5A B) and <br /> increase colonosphere size number IMP1 overexpression                 LoVo (data shown) IMP1 overexpression cell lines, suggesting <br />  <br />  <br />  <br />  <br /> Fig.&#194;&#160;3.&#226;&#8364;&#8218; IMP1 modulates tumor dissemination blood. Blood collected xenograft mice euthanasia number circulating tumor cells <br /> quantified using fluorescence-activated cell sorting GFP (overexpressing cells) RFP (knockdown cells). (A) There increase number of <br /> circulating tumor cells mice harboring IMP1 overexpressing tumors. N &#226;&#8240;&#165; 3 mice group. (B) In mice IMP1 knockdown tumors, significant <br /> decrease number circulating tumor cells detected blood euthanasia. *P &lt; 0.05, N &#226;&#8240;&#165; 3 mice group. <br />  <br />  <br />  <br />  <br /> Fig.&#194;&#160;4.&#226;&#8364;&#8218; IMP1 promotes colonosphere growth passaging. Xenograft tumors dissociated single cells grown serum-free, ultralow attachment <br /> conditions. (A) Individual tumor cells evaluated 10&#194;&#160;days sphere growth, followed mechanical disruption, passaging evaluation sphere <br /> growth spreading 14&#194;&#160;days. Scale bars&#194;&#160;=&#194;&#160;50 &#206;&#188;M. (B) There difference sphere number (C) size IMP1 overexpressing tumor cells compared <br /> with controls. (D) We observed significant increase outgrowth mechanically passaged colonospheres IMP1 overexpressing cells compared with <br /> controls. *P &lt; 0.05, N = 3 individual tumors condition. <br />  <br />                                                                                                                                                       2651 <br />  K.E.Hamilton et&#194;&#160;al. <br />  <br />  <br />  <br />  <br /> Fig.&#194;&#160;5.&#226;&#8364;&#8218; IMP1 overexpression promotes tumor-initiating phenotype. Based findings colonospheres, sought characterize effect of <br /> IMP1 overexpression TIC phenotype vitro. (A B) Control IMP1 overexpressing cells evaluated cell surface expression CD24 and <br /> CD44, markers TICs. IMP1 overexpression dramatically enhanced proportion cells expressing high levels CD24 CD44 compared with <br /> controls. *P &lt; 0.05, N = 3. (C) CD24+CD44+high cells sorted grown two-dimensional culture conditions. Cells passaged times, with <br /> analysis CD24+CD44+high cells passage control IMP1 overexpressing cell lines. There significant increase ability IMP1 <br /> overexpressing cells maintain CD24+CD44+high phenotype compared controls. *P &lt; 0.05, N = 3 passages. <br />  <br />  <br /> that IMP1 does promote TIC phenotype, confer                 proapoptotic functions associated previously IMP1 <br /> prosurvival advantage cells disseminate the&#194;&#160;blood.                  knockdown vitro (17,32). Using xenograft genetic models of <br />    In order test IMP1 promotes stabilization TIC pheno-                CRC, demonstrate IMP1 overexpression promotes increased <br /> type course multiple passages, sorted passaged                 tumor growth, Imp1 knockdown limits tumor growth. In addition, <br /> CD24+CD44+high cells control IMP1 overexpressing                    IMP1 overexpression enhances tumor dissemination blood, <br /> cell lines (Figure&#194;&#160; 5C). We consistently observed IMP1 overex-               increases survival outgrowth individual tumor clones and <br /> pressing cells maintained greater proportion CD24+CD44+high                  enriches population CD24+CD44+ TICs. Together, findings <br /> cells passaging, control cells appeared lose phe-            provide rationale IMP1 correlated <br /> notype time. This supports finding IMP1 enhances                poor survival prognosis CRC patients (10,17) suggest <br /> longevity cell population colonospheres (Figure&#194;&#160;4D),           IMP1 potential driver robust, therapy-resistant TICs. <br /> as cells grown two-dimensional culture conditions.                             Our previous studies indicated IMP1 loss decreased <br />    Tumor dissemination associated TIC phenotype and/              proliferation colony formation CRC cells vitro, thus <br /> or epithelial mesenchymal transition (EMT) phenotype (20).                  hypothesized xenograft studies IMP1 overexpression may <br /> We used qRT&#226;&#8364;&#8220;PCR examine EMT IMP1 cell lines                       promote increased tumor growth potentially enhanced tumor <br /> and saw significant downregulation E-cadherin IMP1                   progression. In SW480 cells, observed increase tumor load <br /> overexpressed, indicating cells losing &#226;&#8364;&#732;epi-              IMP1 overexpression time course 8 weeks, trend <br /> thelial&#226;&#8364;&#8482; phenotype (Figure&#194;&#160;6A). We observed trend concomitant               increased tumor load early 2.5 weeks LoVo cell tumors <br /> upregulation EMT genes vimentin, Snail, Slug Zeb1,                (Figure&#194;&#160;1B; Supplementary Figure S1B, available Carcinogenesis <br /> these statistically significant (Figure&#194;&#160; 6B&#226;&#8364;&#8220;E). Further,              Online). However, SW480 cells inducible IMP1 knockdown, <br /> were able detect Zeb2 cells (data shown). Taken               observed inconclusive results (Supplementary Figure S2B, <br /> together, upregulation CD24+CD44+ markers downregula-                  available Carcinogenesis Online). In knockdown tumors, we <br /> tion E-cadherin suggest IMP1 overexpression promotes                 observed enhanced necrosis decreased viability IMP1 loss <br /> an acquisition &#226;&#8364;&#732;stem-like&#226;&#8364;&#8482; phenotype loss epithelial                (Supplementary Figure S2C&#226;&#8364;&#8220;E, available Carcinogenesis Online), <br /> characteristics, support novel role high-IMP1-               surprising considering previous vitro work in <br /> expressing tumor cells tumor progression.                                      observed IMP1 loss increased apoptosis (17). Increased <br />                                                                                   cell death associated IMP1 loss does not, however, appear to <br /> Discussion                                                                        lead overall decrease xenograft tumor size, suggesting <br />                                                                                   potential compensatory mechanisms IMP1 loss cells. We <br /> The studies suggest oncogenic role IMP1 vivo,                    turned genetic mouse model Imp1 depletion during <br /> providing additional functional insight role CRC progression          intestinal tumorigenesis: conditional Imp1 knockdown mice crossed <br />  <br /> 2652 <br />                                                                                                                      IMP1 colorectal cancer cell xenografts <br />  <br />  <br />  <br />  <br /> Fig.&#194;&#160;6.&#226;&#8364;&#8218; IMP1 overexpression decreases E-cadherin expression. We evaluated IMP1 overexpression promotes EMT vitro. SW480 cells overexpressing <br /> IMP1 analyzed E-cadherin, vimentin, snail, slug zeb1 gene expression order assay loss epithelial phenotype gain mesenchymal <br /> phenotype. Glyceraldehyde 3-phosphate dehydrogenase used internal control. (A) E-cadherin significantly decreased IMP1 overexpression. <br /> *P &lt; 0.05, N = 3. (B&#226;&#8364;&#8220;E) We observed trend upregulation EMT gene IMP1 overexpressing cells. <br />  <br />  <br /> with APCMin/+ mice (Imp1-loxP+/&#226;&#710;&#8217;;Villin-Cre+/&#226;&#710;&#8217;;ApcMin/+ mice). These                 Several mechanisms act concert promote tumor dissemi- <br /> mice exhibited dramatic reduction tumor number compared                      nation blood subsequent metastatic growth. Early tumor <br /> with Villin-Cre+/&#226;&#710;&#8217;ApcMin/+ littermates. Taken together, combined              dissemination linked tumor cells adopting mesenchy- <br /> xenograft genetic mouse models provide novel evidence                    mal phenotype (20); however, factors existence of <br /> IMP1 modulates CRC tumor growth vivo.                                          subpopulation TICs (31,38) proposed critical <br />    We IMP1 overexpression increased IMP1                      components cancer metastasis. We evaluated clonogenic growth <br /> knockdown decreased number tumor cells circulating                  dissociating xenograft tumors evaluating growth individual <br /> blood, independent IMP1&#226;&#8364;&#8482;s effect primary xenograft tumor size               clones subsequent progeny. Although did observe <br /> (Figure&#194;&#160;3). Several recent studies reported tumor cells             significant difference number clones giving rise colo- <br /> enter circulation prior concurrent malignant growth,               nospheres IMP1 overexpression (Figure&#194;&#160; 4B), sig- <br /> challenging current dogma tumor progression localized                 nificant increase survival outgrowth IMP1 overexpressing <br /> disease followed distal metastasis (20,33,34). In current                  clones postpassage (Figure&#194;&#160; 4D), suggesting IMP1 favor <br /> xenograft studies, did observe gross metastases 8 week              long-term growth and/or expansion individual clones. <br /> time course, rule existence micrometastases                 To substantiate vivo findings, explored whether <br /> or eventual metastases arise &#226;&#8364;&#732;dormant&#226;&#8364;&#8482; TICs. A&#194;&#160;second             IMP1 overexpression promotes TIC phenotype and/or EMT vitro. <br /> possibility lack observation gross metastases model              Gene expression E-cadherin downregulated IMP1 overex- <br /> could circulating tumor cells lacked appropriate distal           pression (Figure&#194;&#160;6); however, did observe increase mesen- <br /> metastatic niche, studies suggest critical component           chymal genes cells vitro. E-cadherin loss signifies loss of <br /> for establishment metastatic lesions (35&#226;&#8364;&#8220;37). Future studies            intercellular contacts, event promote metastatic <br /> genetic mouse models required determine IMP1-mediated               phenotype (39). More strikingly, observed IMP1 overexpres- <br /> tumor dissemination lead metastases additional                 sion promoted dramatic increase percentage CD24+CD44+ <br /> &#226;&#8364;&#732;hits&#226;&#8364;&#8482; required.                                                           cells (Figure&#194;&#160; 5A B), indicating IMP1 favor enhance <br />  <br />                                                                                                                                                          2653 <br />  K.E.Hamilton et&#194;&#160;al. <br />  <br />  <br />  <br /> for population TICs. Furthermore, IMP1 overexpression promotes                      	13.	 Vainer,G. et&#194;&#160; al. (2008) A role VICKZ proteins progression of <br /> maintenance phenotype course passages                                                       colorectal carcinomas: regulating lamellipodia formation. J. Pathol., 215, <br /> (Figure&#194;&#160; 5C). This intriguing IMP1 shown previ-                                                     445&#226;&#8364;&#8220;456. <br /> ously bind stabilize CD44 mRNA vitro,                        	14.	 Noubissi,F.K. et&#194;&#160;al. (2006) CRD-BP mediates stabilization betaTrCP1 <br />                                                                                                                         c-myc mRNA response beta-catenin signalling. Nature, 441, <br /> study, IMP1 depletion associated decreased invadopodia for-                                                    898&#226;&#8364;&#8220;901. <br /> mation (40). It possible IMP1 overexpression promotes                    	15.	 St&#195;&#182;hr,N. et&#194;&#160; al. (2012) IGF2BP1 promotes cell migration regulating <br /> a TIC phenotype studies stabilization CD44&#194;&#160;mRNA.                                                      MK5 PTEN signaling. Genes Dev., 26, 176&#226;&#8364;&#8220;189. <br />    Taken together, studies provide novel vivo data suggesting                      	16.	 Manieri,N.A. et&#194;&#160;al. (2012) Igf2bp1 required induction Ptgs2 <br /> that IMP1 modulates tumor growth dissemination tumor cells                                                       mRNA colonic mesenchymal stem cells mice. Gastroenterology, 143, <br /> into blood. Our finding IMP1 overexpression promotes shift                                                   110&#226;&#8364;&#8220;21.e10. <br /> toward TIC phenotype explain clinical findings correlating high                        	17.	 Mongroo,P.S. et&#194;&#160; al. (2011) IMP-1 displays cross-talk K-Ras and <br /> IMP1 poor prognosis clinical outcome CRC patients                                                        modulates colon cancer <span id='am-81' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-82' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-83' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-84' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-85' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-86' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-87' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-90' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-91' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-92' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-93' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-95' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-96' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-97' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-98' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-99' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-100' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-101' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-103' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-104' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-105' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-107' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-108' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-110' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-111' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-113' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-114' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-115' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-116' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-117' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-123' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-124' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-125' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-126' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-127' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-128' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-131' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-133' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-135' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-136' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-138' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-139' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-140' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-141' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-143' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-144' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-146' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-149' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-150' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-151' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-154' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-155' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-156' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span>cell survival</span> novel proapoptotic protein <br /> underscores potential role IMP1 early metastatic events                                                CYFIP2. Cancer Res., 71, 2172&#226;&#8364;&#8220;2182. <br />                                                                                               	18.	 King,C.E. et&#194;&#160; al. (2011) LIN28B promotes colon cancer progression and <br /> marker aggressive therapeutic-resistant cell population.                                                  metastasis. Cancer Res., 71, 4260&#226;&#8364;&#8220;4268. <br />                                                                                                	19.	 Spiegelman,V.S. et&#194;&#160; al. (2000) Wnt/beta-catenin signaling induces the <br /> Supplementary material                                                                                                  expression activity betaTrCP ubiquitin ligase receptor. Mol. Cell, 5, <br />                                                                                                                         877&#226;&#8364;&#8220;882. <br /> Supplementary Figures 1 2 http://carcin.oxford-                             	20.	 Rhim,A.D. et&#194;&#160;al. (2012) EMT dissemination precede pancreatic tumor <br /> journals.org/                                                                                                           formation. Cell, 148, 349&#226;&#8364;&#8220;361. <br />                                                                                                  	21.	 Kanwar,S.S. et&#194;&#160;al. (2010) The Wnt/beta-catenin pathway regulates growth <br />                                                                                                                         maintenance colonospheres. Mol. Cancer, 9, 212. <br /> Funding                                                                                           	22.	 Leibovitz,A. et&#194;&#160;al. (1976) Classification human colorectal adenocarci- <br />                                                                                                                         noma cell lines. Cancer Res., 36, 4562&#226;&#8364;&#8220;4569. <br /> National Institutes Health (T32 DK007066, F32 DK093207-01                                       	23.	 Noubissi,F.K. et&#194;&#160; al. (2009) Wnt signaling stimulates transcriptional out- <br /> to K.E.H.; K08 DK088945 A.D.R.; R01 DK056645-12, U01                                                                 come Hedgehog pathway stabilizing GLI1 mRNA. Cancer Res., <br /> DK085551, P30 DK050306 K.E.H., P.S.K., C.M.H., S.R.D.,                                                               69, 8572&#226;&#8364;&#8220;8578. <br /> E.T.L., A.J.K.-S., A.D.R., A.K.R.; CA153102 F.K.N.; AR063361                                     	24.	 Li,D. et&#194;&#160; al. (2009) IMP3 novel prognostic marker correlates <br /> to V.S.S.); Hansen Foundation National Colon Colon Research                                                         colon cancer progression pathogenesis. Ann. Surg. Oncol., 16, <br /> Alliance A.K.R.                                                                                                      3499&#226;&#8364;&#8220;3506. <br />                                                                                                      	25.	 Lochhead,P. et&#194;&#160; al. (2012) Insulin-like growth factor 2 messenger RNA <br />                                                                                                                         binding protein 3 (IGF2BP3) marker unfavourable prognosis in <br /> Acknowledgements                                                                                                        colorectal cancer. Eur. J.&#194;&#160;Cancer, 48, 3405&#226;&#8364;&#8220;3413. <br />                                                                                                       	26.	Faltas,B. (2012) Cornering metastases: therapeutic targeting circulating <br /> We thank A.Bedenbaugh, D.Budo R.Hasan (Penn Molecular Pathology                                                     tumor cells stem cells. Front. Oncol., 2, 68. <br /> and Imaging Facility) IHC; P.Hallberg (Penn Flow Cytometry Sorting                             	27.	 Yu,Y. et&#194;&#160;al. (2009) Elimination colon cancer stem-like cells com- <br /> Facility); D.&#194;&#160; Heitjan (Penn Biostatistics); S.Keilbaugh (Penn Molecular                                                bination curcumin FOLFOX. Transl. Oncol., 2, 321&#226;&#8364;&#8220;328. <br /> Biology Core) E.Roberston (Penn Cell Culture Core).                                                 	28.	 Weichert,W. et&#194;&#160;al. (2005) Cytoplasmic CD24 expression colorectal can- <br />                                                                                                                         cer independently correlates shortened patient survival. Clin. Cancer <br /> Conflict Interest Statement: None declared.                                                                          Res., 11, 6574&#226;&#8364;&#8220;6581. <br />                                                                                                          	29.	 Choi,D. et&#194;&#160;al. (2009) Cancer stem cell markers CD133 CD24 correlate <br /> References                                                                                                              invasiveness differentiation colorectal adenocarcinoma. World <br />                                                                                                                         J.&#194;&#160;Gastroenterol., 15, 2258&#226;&#8364;&#8220;2264. <br /> 	 1.	Leeds,P. et&#194;&#160; al. (1997) Developmental regulation CRD-BP, RNA-                                  	30.	 Herrmann,I. et&#194;&#160;al. (2010) Highly efficient elimination colorectal tumor- <br />         binding protein stabilizes c-myc mRNA vitro. Oncogene, 14,                                              initiating cells EpCAM/CD3-bispecific antibody engaging human T <br />         1279&#226;&#8364;&#8220;1286.                                                                                                      cells. PLoS One, 5, e13474. <br /> 	 2.	Ross,A.F. et&#194;&#160; al. (1997) Characterization beta-actin mRNA zipcode-                               	31.	 Yeung,T.M. et&#194;&#160;al. (2010) Cancer stem cells colorectal cancer-derived <br />         binding protein. Mol. Cell. Biol., 17, 2158&#226;&#8364;&#8220;2165.                                                               cell lines. Proc. Natl Acad. Sci. USA, 107, 3722&#226;&#8364;&#8220;3727. <br /> 	 3.	Doyle,G.A. et&#194;&#160; al. (1998) The c-myc coding region determinant-binding                                  	32.	 Boyerinas,B. et&#194;&#160;al. (2012) Let-7 modulates acquired resistance ovarian <br />         protein: member family KH domain RNA-binding proteins.                                                cancer Taxanes  <br /> </body></html>